Abstract
Acarbose is a glucosidase inhibitor which exerts its activities within the gastrointestinal tract on brush-border digestion and absorption of sucrose and maltose. Only 1%–2% of the drug is absorbed from the intestine into the systemic circulation. This low systemic availability is, of course, not relevant for the therapeutic effect of the substance, but possibly is relevant for the systemic side effects. Therefore, it is important to investigate the effect of acarbose on the metabolism of patients in whom elevated liver enzymes could be a reference for possible impairments of liver function.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Haupt, E., Hillebrand, I., Pfeffer, H. (1988). Effectiveness and Tolerability of the α-Glucosidase Inhibitor Acarbose in NIDDM Patients with Elevated Liver Enzyme Activity. In: Creutzfeldt, W. (eds) Acarbose for the Treatment of Diabetes Mellitus. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73583-7_45
Download citation
DOI: https://doi.org/10.1007/978-3-642-73583-7_45
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-19145-2
Online ISBN: 978-3-642-73583-7
eBook Packages: Springer Book Archive